Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,796Revenue (TTM) $M21.8Net Margin (%)-567.0Altman Z-Score11.1
Enterprise Value $M1,419EPS (TTM) $-2.7Operating Margin %-1,131.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score11.4Pre-tax Margin (%)-557.9Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %6.6Quick Ratio5.7Cash flow > EarningsN
Price/Sales83.65-y EBITDA Growth Rate %35.4Current Ratio6.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-43.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M55.0ROIC % (ttm)-726.6Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SRPT is held by these investors:



SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-34.74view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-45.53view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-45.53view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-45.53view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-34.64view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-34.64view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-34.64view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$308.93view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.28100.74view
Barry RichardDirector 2016-03-14Buy75,000$15.66108.68view

Press Releases about SRPT :

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Perceptive and Edelmen's Next NASDAQ IPO Debutant May 04 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 01 2017 
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Development Apr 27 2017 
Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, I Apr 18 2017 
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developme Apr 17 2017 
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Apr 05 2017 
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical O Apr 03 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2017 
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to t Mar 30 2017 
Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference Mar 17 2017 

More From Other Websites
Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today May 22 2017
Top hedge fund managers shared these 5 trade ideas at the SALT Conference May 20 2017
SALT Spotlight: Why Sarepta is a Buy May 18 2017
Big Fund Managers Offer Up Stock Pick Ideas May 18 2017
Tourbillon's Karp says Sarepta shares could surge 200 pct May 18 2017
How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked May 18 2017
​Former Sarepta CEO launches biotech accelerator with $25M backing May 18 2017
Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 May 14 2017
Should You Buy Into the Hype Surrounding These Stocks? May 06 2017
Sarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why. May 06 2017
Edited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT May 03 2017
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 01 2017
How Much Would Sarepta Therapeutics Fetch in a Buyout? May 01 2017
Sarepta: Forget a Takeover. This is Why Its CEO's Departure Could Be Good News May 01 2017
Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics May 01 2017
Sarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide Apr 28 2017
Sarepta Tests Biotech's CEO Vacuum Hypothesis Apr 28 2017
​Sarepta shares jump as CEO’s planned exit spurs takeover speculation Apr 28 2017
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Apr 28 2017
Yes, Sarepta Reported Earnings…But That's Not Why It's Flying Today Apr 28 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat